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a  b  s  t  r  a  c t
Introduction:  Stage  III  NSCLC  patients  are  candidates  for treatment  with  curative  intent.  Current  guidelines
advise  post  contrast  magnetic  resonance  imaging  (MRI)  or contrast  enhanced  computed  tomography
(CE-CT)  of  the  brain  in  these  patients  to exclude  brain  metastases  (BM).  In previous  small  studies
MRI  was  reported  to  be  superior  to  CE-CT.  However,  CT and MR technology  have  evolved  and 18F-
deoxyglucose-positron-emission-tomography  (18FDG-PET)  has been  implemented  in staging  of  NSCLC.
If  CE-CT,  performed  together  with 18FDG-PET-CT  shows  the  same  yield  of BM  detection  as  an  additionally
performed  MRI,  substantial  gain  in  time  and resources  is  expected.
Methods:  All  NSCLC  patients  who  underwent  a staging 18FDG-PET-CT  between  January  2008  and
September  2011  were  reviewed.  Neurological  asymptomatic  patients  with  stage  III  NSCLC  who  were
eligible  for  treatment  with  curative  intent  were  selected,  without  taking  into  account  the  results  of  brain
MRI.  CT  was  compared  to MRI  to investigate  whether  additional  BM were  detected  on  MRI.  Development
of  BM  within  a year  after  negative  MRI  was  recorded.
Results: 97/429  NSCLC  patients  who  underwent  a  PET-CT  had  stage  III  disease.  Three  otherwise  stage  III
patients  already  had  occult  BM  on  CE-CT.  77/97  (79%)  patients  underwent  MRI,  45/77  (58%)  CE-CT  and
32/77  (42%)  LD-CT.  In  none  of the  CE-CT,  but  in  5/32 (16%)  LD-CT  patients  BM  were  detected  on  MRI. 9/72
patients  (13%)  without  BM  on MRI  at  diagnosis  developed  BM within  a year.
Conclusions:  This  retrospective  study  suggests  that there  is no  additive  value  of  MRI  to 18FDG-PET-CT  with
 in nCE-CT  in  screening  for BM
. Introduction
Around 30% of patients with non small cell lung cancer (NSCLC)
resent with stage III disease and are candidates for intense com-
ined modality treatment with curative intent [1]. The outcome is
owever still poor, with 5 year survival rate of 15.1% [1].
As the brain is a common site for dissemination [2], national and
nternational guidelines advise to exclude brain metastases before
tarting intense treatment in this patient population. The com-
ined modality treatment with concurrent chemoradiotherapy is
∗ Corresponding author at: Maastricht University Medical Centre+, P.O. Box 5800,
202 AZ Maastricht, The Netherlands. Tel.: +31 033871318; fax: +31 033875051.
E-mail address: lizza.hendriks@mumc.nl (L.E.L. Hendriks).
169-5002/$ – see front matter ©  2013 Elsevier Ireland Ltd. All rights reserved.
ttp://dx.doi.org/10.1016/j.lungcan.2013.02.006eurological  asymptomatic  patients  with  stage  III NSCLC.
© 2013 Elsevier Ireland Ltd. All rights reserved.
frequently associated with morbidity due to radiation esophagitis
and pneumonitis [3–5]. It is estimated that, dependent on dis-
ease stage and choice of radiological evaluation, 10–24% of NSCLC
patients at presentation have one or more asymptomatic brain
metastases [2,6,7]. For example, up to 16% otherwise stage III NSCLC
patients were diagnosed with brain metastases on post contrast
magnetic resonance imaging (MRI). However, in this study pub-
lished in 2003, the number of patients with stage III NSCLC was
small (38 of 91 patients) and 18F-deoxyglucose-positron emission
tomography (18FDG-PET) scanning was not performed to exclude
extracranial metastases [2].A whole body 18FDG-PET is in current guidelines advised in
the diagnostic work up of all patients eligible for therapy with
curative intent to exclude extracranial metastases [3–5] 18FDG-
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rain metastases [8,9] Nowadays, combined PET-CT scanners are
ore frequently used. In these scanners a 18FDG-PET can be per-
ormed with a non-diagnostic low dose computed tomography
LD-CT) for attenuation correction or with a diagnostic contrast
nhanced CT (CE-CT) of the thorax and upper abdomen. Combina-
ion with CE-CT of the brain is also an option and feasible, but is not
ommon practice [10]. 18FDG-PET-scanning with LD-CT for atten-
ation correction has already been proven not to be effective in
etecting asymptomatic brain metastases when compared to MRI
11].
Post contrast MRI  is reported to be superior to CE-CT in diag-
osing occult brain metastases. However, these were mostly older
tudies, all including patients with mixed tumour types and tumour
tages [7,12–14].
In addition, CT and MR  technology both have evolved sig-
ificantly. Moreover, in none of the studies mentioned above a
8FDG-PET(-CT) was part of the diagnostic work up, leading to a
ess well staged patient population [15].
Lung cancer guidelines advice routine screening for brain metas-
ases with post contrast MRI  or CE-CT in all patients with stage
II NSCLC eligible for therapy with curative intent [3–5,15,16]. In
 guidelines, NCCN, ESMO and the Dutch VIKC, a post contrast
RI  is advised [4,5,16]. However, in most hospitals MRI is difficult
o arrange within a reasonable time scale. There are also contra-
ndications for MRI  as intracorporal metallic objects, pacemakers
nd claustrophobia.
The question whether post contrast MRI  offers a benefit to CE-
T in the initial staging of patients with NSCLC has become more
rgent in view of the increasing wide-spread use of 18FDG-PET-CT
canners. If dedicated CE-CT of the brain performed in the same
etting as 18FDG-PET-CT could lead to the same yield of detec-
ion of brain metastases as 18FDG-PET-CT with a non-diagnostic
D-CT for attenuation correction and a separate post contrast MRI,
 substantial gain in time and resources can be expected. In this
etrospective study we evaluated whether there is additive value
f post contrast MRI  to CE-CT for the detection of asymptomatic
rain metastases when both are performed in standard work-up
ncluding 18FDG-PET-CT.
. Materials and methods
.1. Patient selection
The 18FDG-PET-CT database of the university hospital Maas-
richt, The Netherlands, was reviewed. All patients who underwent
8FDG-PET-CT in the diagnostic work-up for lung cancer between
anuary 2008 and September 2011 were further evaluated. Patients
ith stage III NSCLC disease after staging with the 18FDG-PET-
T and who were candidates for treatment with curative intent
ere selected. Patients with neurological symptoms requiring
rain imaging were excluded. In our hospital standard work-up of
atients admitted with suspicion of lung cancer includes a 18FDG-
ET according to a specific lung cancer protocol which consists of
 CE-CT of the brain, thorax and upper-abdomen combined with
he 18FDG-PET. In case a CE-CT of the chest and upper abdomen
s already performed separately the 18FDG-PET is combined with
 non-diagnostic LD-CT for attenuation correction. As a conse-
uence, in these cases only a non-diagnostic LD-CT of the brain
as available. Both patients who underwent a LD-CT together with
he PET-CT and patients who underwent a CE-CT were analyzed.
he policy in our institute is to screen for brain metastases in oth-
rwise stage III NSCLC patients by MRI, also when a CE-CT of the
rain is already performed. The results of the MRI  were studied
o investigate whether additional asymptomatic brain metastasescer 80 (2013) 293– 297
were detected on MRI. In addition development of symptomatic
brain metastases within a year after a negative scan was  scored.
This study has been approved by the medical ethical committee
of the university hospital Maastricht.
2.2. Imaging protocols
2.2.1. MRI protocol
MRI  was  performed with a 1.5 T MRI  system using a 8-channel
Sens head coil (Philips Healthcare, Best, The Netherlands). The
protocol included a T1 weighted spin-echo sequence with a mag-
netization prepulse ((MTC) (TR 615, TE 14, NEX 2, matrix 2568154,
with an on resonance prepulse), with and without 0.1 mmol/kg
body weight of Gadobutrol. The addition of the MTC  prepulse
results in an increased enhancement equivalent to a double doses
of gadolinium contrast. Additionally a T2 weighted turbo-spin echo
sequence (TR 4632, TE 100, ETL 12, NEX 2, matrix 256 × 192) and
a fluid attenuated inversion recovery sequence (TR 8000, TE 120,
TI 2000, ETL 23, NEX 1, matrix 512 × 138). All sequence had a slice
thickness of 5 mm with a gap of 0.5 mm.  Additionally a T1 weighted
gradient echo sequence was  performed with isotropic voxels of
1 mm (TR 9, TE 4, NEX 1, matrix 256 × 256).
2.2.2. PET-CT protocol
Acquisition of 18FDG-PET-CT was  performed using a PET camera
equipped with time-of-flight (Gemini TF PET/64-slice CT scanner,
Philips, Best, The Netherlands). PET scans were made from head
to pelvis, using 10 bed positions of 2.5 min each, after injection
of 18FDG. In selected cases imaging was continued. Reconstruction
was performed using a standard protocol in 3D with a matrix size of
144 resulting in a voxel size of 4.0 mm× 4.0 mm× 4.0 mm.  PET was
preceded by a LD-CT (120 keV, 30 mAs, 4 mm slice thickness, 4,0
increment) for attenuation correction of the PET images. Supple-
mentary high-dose, CE-CT was  performed according to a protocol
with a standardized sequence following injection of 150 ml  and a
flow rate of 3 ml/s of jopromide (Ultravist, Bayer, Berlin, Germany):
The diagnostic brain CT (120 kV, 400 mAs) was performed with a
slice thickness of 0.8 mm and reconstructed to 5 mm thick slices.
The scan was  performed 3 minutes after administration of the
jopromide.
3. Results
4131 18FDG-PET-CT scans were reviewed. From the 510 18FDG-
PET-CT’s performed in the diagnostic work-up for lung cancer, 429
patients were diagnosed with NSCLC. 3 patients with otherwise
stage III disease had occult brain metastases on CE-CT. 112 of 429
patients were diagnosed with stage III disease after PET-CT. 97 of
112 (87%) stage III patients were eligible for therapy with curative
treatment. 77 of 97 (79%) patients underwent MRI  (Fig. 1). Patient
characteristics of these 77 patients are shown in Table 1. Although
the standard work-up consisted of a MRI, the MRI  was not per-
formed in 20 patients because of diagnostic work-up elsewhere
(n = 3), contra-indication for MRI  (n = 2), participation in a study in
which MRI  of the brain was  not a requisite (n = 5), deterioration of
clinical condition before MRI  was  made (n = 2) or patient decision
not to undergo therapy with curative intent (n = 2). In 6 patients no
reason was  found for not performing MRI.
In 45 of 77 (58%) patients a CE-CT was performed and in 32
of 77 (42%) patients only a LD-CT was done together with the
18FDG-PET. In the LD-CT patient group a CE-CT of the thorax and
upper abdomen was  already available before the 18FDG-PET-CT was
made. In these cases only a LD-CT was performed combined with
the 18FDG-PET for attenuation. As a consequence, no diagnostic
scan of the brain was available in these patients.
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Fig. 1. Flowchart work-u
Table 1
patient characteristics stage III NSCLC patients in whom MRI  was made.
Sex (male/female) 46/31
Age (years) range 64.9 range 10.2






















Squamous cell carcinoma 24









No  treatment 1
Abbreviations: WHO: World Health Organization; NOS: not otherwise specified.
a The clinical condition of these patients deteriorated quickly during analysis, so
only palliative treatment was offered.p stage III NSCLC.
In the negative CE-CT group, 19 of 45 patients (42%) had stage
IIIA disease and 26 (58%) had stage IIIB. In the LD-CT group, 18 of
32 patients (56%) had stage IIIA disease and 14 (44%) had stage IIIB
(T and N see Table 1).
In none of the 45 patients who had a negative CE-CT of the brain
together with the 18FDG-PET scan, brain metastases were detected
on MRI. In contrast, in 5 of 32 (16%) LD-CT patients brain metastases
were detected on MRI  (Fig. 2). The MRI  showed 2 metastases in 1
patient (largest 16 (mm)), 3 metastases in 1 patient (all around
6 mm)  and multiple metastases in the other 3 patients (largest
12 mm).  Before MRI, these patients were staged as cT1N3, cT2N2,
cT4N0, cT4N2 and cT4N3.
Within 1 year of the diagnosis 9 of 72 (13%) patients without
brain metastases on MRI  at diagnosis developed symptomatic brain
metastases, in 2 of 9 (22%) also progressive disease outside of the
brain was shown (Figs. 3 and 4). Of these 9 patients, 2 were ini-
tially diagnosed with a squamous cell carcinoma (initially cT2N3M0
and cT4N0M0), 4 with an adeno carcinoma (initially cT4N2M0,
cT2N2M0, cT4N2M0, cT4N0M0) and in the remaining 3 patients the
NSCLC was  not otherwise specified (initially cT2N2M0, cT2N2M0,
cT3N2M0). Of these 9 patients, 3 had a CE-CT followed by MRI  dur-
ing their initial work-up for lung cancer, 6 had a LD-CT followed
by MRI  during the initial work-up. To evaluate whether these brain
metastases were missed during the initial work-up the imaging
data of these 9 MRI’s were reviewed by an experienced neuro-
radiologist (PH), but also in retrospect no brain metastases were
found.
4. Discussion
Brain metastases are frequent in stage III NSCLC [2]. Histor-
ically MRI  is supposed to be superior to CT in detecting brain
metastases [2,7,12,14]. However, the question is whether MRI
has a clinical relevant benefit above CE-CT in detecting asymp-
tomatic brain metastases in stage III NSCLC when using up-to-date
staging techniques. In this study, up-to-date MRI  and CT tech-
niques were used and extra-cranial metastases were excluded by
296 L.E.L. Hendriks et al. / Lung Cancer 80 (2013) 293– 297






Fig. 3. Brain metastases with
8FDG-PET-CT scanning. In this patient population MRI  did not
how additional brain metastases after a negative CE-CT of the brain
ombined with the 18FDG-PET-CT, but in three of 48 patients brain
etastases were already found on the CE-CT.
Fig. 4. Kaplan Meier curve, time to develop symptomatic brain metastasis.ar after initial negative MRI.
Also, this study confirms that adequate imaging of the brain is
mandated in these patients as in 16% of the patients who  underwent
solely a non diagnostic LD-CT of the brain, brain metastases were
detected on MRI. This percentage is comparable to percentages of
occult brain metastases found in other studies [2].
Substantial gain in time and resources can be expected when
the whole diagnostic imaging work-up can be performed in one
single procedure, this diagnostic work-up consisting of a 18FDG-
PET directly followed by CE-CT of the brain, thorax and (upper)
abdomen. Following this procedure there would also be no delay
because of waiting time for MRI  before starting therapy with cura-
tive intent. Furthermore, in most institutes access to CT is easier
than to MRI.
Brain metastases are still a serious problem in patients with
stage III NSCLC, in our series 13% of patients with an initially neg-
ative MRI  developed brain metastases within a year. Probably it
is worth to investigate whether these brain metastases can be
detected at diagnosis when more sensitive MRI  techniques are
used. It is known that the sensitivity of a post contrast MRI can be
increased by using higher dose of contrast or by 3.0 T MRI  instead
of 1.5 T. However, higher contrast doses also increases false posi-
tive findings [9,17,18]. Moreover, although 3.0 T MRI  scanners seem
more sensitive in detecting cerebral lesions, no studies exist that
show the increased sensitivity of 3.0 T systems for the detection
of cerebral metastases. In our study we  used MTC  prepulse, this
prepulse results in an increased enhancement equivalent to a dou-
ble dose of gadolinium contrast [19]. The addition of post-contrast
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sed) also improves diagnostic confidence in the evaluation of
rain metastases [20]. Another option is to routinely follow stage
II NSCLC patients treated for cure with MRI  or CE-CT of the brain on
 regular basis to detect brain metastases at a stage where radical
reatment is possible. Trying to prevent the development of brain
etastases is also an option. A recent phase III study showed that
rophylactic cranial irradiation in NSCLC stage III without progres-
ive disease after therapy decreased the rate of brain metastases but
o effect on overall survival or disease free survival was  found [21].
nother phase III randomized study addressing the same question
s still open for patient enrolment (NVALT11/DLCRG 02).
There are some drawbacks of the current study. First, it is a
etrospective study with a small sample size. However all con-
ecutive patients were included in the analysis, decreasing the
isk of bias. Second, not all stage III underwent a MRI. This was
specially in 2008 when guidelines did not already advise post con-
rast MRI  of the brain to exclude brain metastases. Third, not all
atients were screened by CE-CT before MRI. In the LD-CT group
 CE-CT of the thorax and upper abdomen was already available
efore the 18FDG-PET-CT was made (most times because the CT
f the chest was made for other purpose than suspicion of can-
er). In these cases the 18FDG-PET was only combined with a
on-diagnostic LD-CT for attenuation. As a consequence no diag-
ostic scan of the brain was available. There were no differences
n patient characteristics between the patients with LD-CT and
E-CT.
. Conclusion
This retrospective study of a consecutive cohort of patients
uggests that there is no additive value of post contrast MRI
hen 18FDG-PET-CT with CE-CT is performed in the diagnos-
ic work-up of neurologically asymptomatic stage III NSCLC
atients in screening for brain metastases. However, brain
etastases is still an important problem as 13% of patients
eveloped symptomatic brain metastases within 1 year after
reatment with curative intent. Due to the possible impact of
hese findings on clinical practice a prospective trial (NTR3628)
sing up-to-date imaging techniques to validate these data has
tarted.
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